Background: Elderly patients with non-Hodgkin’s lymphoma (NHL) are often excluded from or underrepresented in clinical trials of combination chemotherapy regimens because of toxicity of the treatment. Materials and Methods: We report our results in a cohort of 32 patients aged over 60 years who received mitoxantrone, etoposide and prednisolone as first-line therapy and of another 14 patients with relapsed NHL as salvage therapy. 26 patients had high-grade NHL and 20 had low-grade NHL. Advanced stage was defined as Ann Arbor stages 3 and 4 and was seen in 38 patients. Results: Patients with NOVEP as first-line therapy achieved 41% complete remissions (CR) and 34% partial remissions (PR), leading to an overall response rate of 75%. Event-free 3-year survival was 29% in this subgroup. Pretreated patients achieved only 7% CR and 14% PR. Two patients died of treatment-related side effects. Conclusions: The combination of mitoxantrone, etoposide and prednisolone is successful in non-pretreated elderly patients with NHL and shows only low toxicity especially for this subgroup, even in advanced stages. It is of minor success as salvage therapy for older patients with relapsed NHL.

Keywords:
Non-Hodgkin’s lymphoma, Elderly patients, Mitoxantrone, Etoposide, Prednisolone
This content is only available via PDF.
© 1993 S. Karger AG, Basel
1993
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.